Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...

Novartis' head of medical affairs Ameet Nathwani talks about the remarkable story of Entresto's accelerated development, and plans for a novel pricing. As the ink dries on the US approval of ...

The global gene therapy market is projected to grow at a significant CAGR of 20% from 2024 to 2029. This growth is driven by ...

Analysts have had to throw out their assumptions for the biopharma industry’s recovery heading into the first quarter ...

Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio. Find out why I give AMGN stock a ...

The psoriasis pipeline possesses some drugs in mid- and late-stage development to be approved in the near future. The emerging landscape holds a dive ...

A three-judge panel wrestled Thursday with Novartis AG’s challenge against the FDA over its approval of a generic version of ...

Having a child recipient and helping someone in need – especially if they knew them – were among the top reasons that people ...

Spruce Biosciences has put out new shoots, snapping up rights to a former BioMarin rare disease candidate and outlining plans ...

Detailed price information for Phio Pharmaceuticals Corp (PHIO-Q) from The Globe and Mail including charting and trades.